Array Biopharma provides NEMO update

Monday, March 20, 2017

Array Biopharma provides NEMO update. Array Biopharma Inc - Has withdrawn from U.S. FDA division of oncology products 2 its new drug application (NDA) for binimetinib monotherapy.

Says ongoing clinical trials for binimetinib will continue.

Array Biopharma Inc - Withdrawl will not impact planned Phase 3 columbus trial NDA of binimetinib.